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Abstract 
Bruton’s tyrosine kinase (BTK) is a cytoplasmic protein found in all 
hematopoietic cell lineages except for T cells. BTK mediates signalling 
downstream of a number of receptors. Pharmacological targeting of BTK 
using ibrutinib (previously PCI-32765) has recently shown encouraging clinical 
activity in a range of lymphoid malignancies. This study reports for the first 
time that ibrutinib is inhibits blast proliferation from human acute myeloid 
leukaemia (AML) and that treatment with ibrutinib significantly augmented 
cytotoxic activities of standard AML chemotherapy cytarabine or daunorubicin. 
Here we describe that BTK is constitutively phosphorylated in the majority of 
AML samples tested, with BTK phosphorylation correlating highly with the 
cell’s cytotoxic sensitivity towards ibrutinib.  BTK targeted RNAi knock-down 
reduced colony forming capacity of primary AML blasts and proliferation of 
AML cell lines. We showed this anti-proliferative affects of ibrutinib in AML is 
mediated via an inhibitory effect on AKT and downstream nuclear factor-κB 
(NF-κB) survival pathways. Moreover, ibrutinib inhibited AML cell adhesion to 
bone marrow stroma. Furthermore, these effects of ibrutinib in AML were seen 
at comparable concentrations that are efficacious in chronic lymphocytic 
leukemia (CLL).  These results reported here provide a biologic rationale for 
the clinical evaluation of BTK inhibition in patients with AML. 
 
Key Points 
 Inhibition of Bruton’s tyrosine kinase is as effective against acute 
myeloid leukemia (AML) as chronic lymphocytic leukemia (CLL) in vitro. 
 Ibrutinib shows similar activity in AML due to its constitutively active 
Bruton’s tyrosine kinase activity. 
 
 3 
Introduction 
Acute myeloid leukemia (AML) is primarily a disease of the elderly with a 
median age at diagnosis in the Swedish Acute Leukemia Registry of 72 years 
(quartile values, 60-79 years; range, 16-97 years) 1. In younger patients (<65 
years old), there is clear evidence of improved survival in the last two or three 
decades, however in the majority group of older patients, there is little 
evidence of similar improvement, and the appropriateness of intensive 
cytotoxic treatment represents a current dilemma 2. Accordingly to improve 
outcomes for all patients (including older patients with AML) there is a 
requirement for more effective treatments with reduced toxicity. Such 
therapies will result from a better understanding of the biology of AML.  
 
Clinically, morphologically and biologically, AML seems to comprise of a 
heterogenous group of tumors. However despite this apparent diversity, AML 
relies on common programs of self-renewal downstream of the driver 
oncogene and further more comprehensive analysis of AML genomes has 
suggested that AML is not a disease caused by hundreds of mutations, but in 
fact only a few 3. These observations would suggest that mechanistically 
common therapeutic approaches are likely to be applicable to broad 
populations of patients with AML, regardless of the identity of the driver 
oncogene/s involved 4.  
 
Tyrosine kinases (TK) are proving to be attractive drugable targets in cancer. 
In AML activating mutations of receptor tyrosine kinases have been identified 
in circa 50% of all patients 5,6.  Furthermore cell survival and proliferation 
pathways dependent on TK activation, including MAPK, phosphoinositide 3-
kinase (PI3K)/AKT, mTOR, NF-κB and STATs are deregulated in most, if not 
all, cases of AML 7-10. These observations suggest that a therapeutic strategy 
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targeting key tumor specific, deregulated receptor TKs and/or non-receptor 
TKs may be both widely applicable and effective in AML patients. 
 
Bruton tyrosine kinase (BTK) belongs to the Tec family of tyrosine kinases 
and clearly has an important function in a number of benign and malignant 
cells of the haematopoietic system. BTK was originally identified in BCR 
signalling as mutations in BTK block B cell development causing a lack of 
circulating immunoglobulins {Vetrie, 1993 #8500}{Tsukada, 1993 #8249}. 
Since then It has been shown an essential mediator of normal B-cell 
development linking the receptor for B cell-activating factor (BAFF) receptor 
(BAFF-R) of the TNF receptor superfamily to the NF-κB pathway 11. The 
properties of other receptors (including some toll-like receptor responses) are 
dependent on BTK.  Recent phase 1 and 2 studies of the irreversible BTK 
inhibitor, ibrutinib have demonstrated promising activity and tolerability against 
a variety of B-cell malignancies including, chronic lymphocytic leukemia (CLL), 
mantle cell lymphoma, hairy cell leukaemia, multiple myeloma and diffuse 
large B-cell lymphoma in younger and older patients alike 12-18. In addition to 
its function in lymphoid cells BTK expression has also been found in 
hematopoietic stem cells (HSC), multipotent progenitors, and in several other 
cells of the haematopoietic system including those of erythroid and 
megakaryocytic lineage 19. Furthermore it has become evident that BTK-
deficiency significantly affects cells in the myeloid compartment including 
LPS-induced toll-like receptor-induced TNF production by monocytes 20, 
regulation of dendritic cell maturation and function via IL-10 and Stat3 21, as 
well as neutrophil development and function 22,23. Moreover high BTK 
phosphorylation and RNA expression has been observed in AML 24,25. Here 
we explain the function of BTK in human AML and describe the 
pharmacological effects of BTK inhibition by ibrutinib on AML proliferation and 
bone marrow adhesion.   
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Methods 
Materials 
The AML-derived cell lines were obtained from the European Collection of 
Cell Cultures where they are authenticated by DNA-fingerprinting.  In the 
laboratory they are used at low passage number for a maximum of 6 months 
post-resuscitation, testing regularly for Mycoplasma infection. Anti-NF-κB and 
AKT antibodies were purchased from Cell Signaling Technologies 
(Cambridge, MA). Anti-BTK (phospho Y223) antibody [EP420Y] and (phospho 
Y551) antibody [EP267Y] was purchased from Abcam (Cambridge, UK). All 
other antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA).  Ibrutinib was obtained from Selleck Chemicals. Stem cell factor (SCF), 
interleukin-1 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-
CSF) and TNF were purchased from Invitrogen. All other reagents were 
obtained from Sigma-Aldrich (St Louis, MO), unless indicated. 
 
Cell culture  
AML cells were obtained from patients bone marrow or blood following 
informed consent and under approval from the UK National Research Ethics 
Service (LRECref07/H0310/146).  For primary cell isolation, heparinized blood 
was collected from volunteers and human peripheral blood mononuclear cells 
(PBMCs) isolated by Histopaque (Sigma-Aldrich, UK) density gradient 
centrifugation. AML samples that were less than 80% blasts were purified 
using the CD34 positive selection kit  (denoted by * in Supplementary Table 
1).   Cell type was confirmed by microscopy and flow cytometry We obtained 
hematopoietic CD34+ cells from two sources, Stem Cell Technologies and 
volunteers.  Positive selection of CD34+ cells were isolated from PBMCs 
using a CD34 positive selection kit (Miltenyi Biotec, Auburn, CA). For all 
CD34+ experiments at least three different donors were used to obtain the 
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results presented in this paper.  Cell type was confirmed by microscopy and 
flow cytometry.   
Human bone marrow stromal cells (BMSCs) were isolated by bone marrow 
aspirates from AML patients.  Mononuclear cells were collected by gradient 
centrifugation and plated in growth medium containing RPMI and 20% FBS 
and 1% l-glut. The non-adherent cells were removed after 2 days. When 60%-
80% confluent, adherent cells were trypsinised and expanded for 3-5 weeks. 
BMSCs were checked for positive expression of CD105, CD73, and CD90 
and the lack of expression of CD45 and CD34 by flow cytometry 26,27.  
 
RNA extraction and real-time PCR 
Total RNA was extracted from 5 x 105 cells using the Nucleic acid Prep 
Station from Applied Biosystems (Paisley, UK), according to the 
manufacturer’s instructions. Reverse transcription was performed using the 
RNA polymerase chain reaction (PCR) core kit (Applied Biosystems). Relative 
quantitative real-time PCR used SYBR green technology (Roche) on cDNA 
generated from the reverse transcription of purified RNA. After 
preamplification (95°C for 2 minutes), the PCRs were amplified for 45 cycles 
(95°C for 15 seconds and 60°C for 10 seconds and 72°C for 10 seconds) on a 
384-well LightCycler 480 (Roche, Burgess Hill, UK). Each mRNA expression 
was normalized against GAPDH mRNA expression using the standard curve 
method. 
 
Western immunoblotting and NF-κB binding assay. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot 
analyses were performed as described previously. Briefly, whole cell lysates 
as well as nuclear and cytosolic were extracted and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis separation performed 28,29. Protein was 
transferred to nitrocellulose and Western blot analysis performed with the 
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indicated antisera according to their manufacturer’s guidelines. To examine 
NF-κB binding in AML cells we used The TransAM NF- κB family 
Transcription Factor assay kit from ActiveMotif.  
 
Immunolocalisation and quantitation of total versus phopho-BTK  
Primary CD34+ cells, AML cell lines and AML primary samples were fixed in 4 
% (w/v) paraformaldehyde, permeablised with 0.1 % (v/v) Triton-X100 and 
blocked with 10 % (v/v) normal goat serum. Samples were stained with 
primary antibodies against total BTK (D3H5) and phosphorylated BTK (Y223) 
(Cell Signalling Technology). Primary antibody binding was visualised with 
secondary Alexa Fluor® 568 and 488 conjugated IgG (H+L) antibodies 
(Invitrogen Molecular Probes), respectively. Cell nuclei were visualised with 
4',6-diamidino-2-phenylindole (DAPI) before samples were mounted with 
FluoromountTM aqueous mounting medium. Cells were stained with 
secondary antibody only to determine non-specific binding which was 
subtracted from the staining intensity analysed for pBTK and total BTK. Cells 
were imaged with the AxioCam ICm 1 monochrome CCD camera attached to 
the Apotome.2 Imaging System using Axiovision 4.8.2 software (all Carl Zeiss 
Ltd). Images were analysed for staining intensity of total versus phosphoBTK 
with ImageJ open source software (NIH) and Area Calculator plugins before 
percentage phopshoBTK was calculated (n=20 per sample).  
 
Proliferation/death assays  
Cells were treated with different doses of ibrutinib then viable numbers 
measured with Cell-Titre GLO (Promega, Southampton, UK).  Flow cytometry 
for measuring apoptosis was performed on the Accuri C6 flow cytometer (BD 
biosciences, Oxford, UK). Samples were collected and stained with annexin- 
V and Propidium Iodide (PI) (Abcam), followed by detection. For the AML-
BMSC co-cultures AML cell viability was measured using flow cytometry.  
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After exclusion of BMSC by electronic gating using forward scatter the extent 
of AML cells apoptosis was measured using annexin-V.  
 
Virus construction and infection 
MicroRNA sequence miRNA-BTK437 (5’-TTCACTGGACTCTTCACCTCT-3’) 
and miRNA-BTK1092 (5’-TGACAATGAAACCTCCTTCTT-3’) targeting human 
BTK was selected with Invitrogen Block-iT RNAi Designer software 
(www.invitrogen.com/rnai) and plasmid pcDNATM6.2-GW/EmGFP-miR-neg 
(Invitrogen) was used as source for negative control. MicroRNA-encoding 
sequences were cloned into Block-iT Pol II miR-RNAi vector (Invitrogen) and 
then EmGFP-pre-miRNA fragments were subcloned into the BamHI/Xho I site 
in the LNT/SffvMCS plasmid (kind gift from Penny Powell, University of East 
Anglia, UK). MicroRNA-encoding viruses were produced in 293T cells as 
described previously 30, using packaging plasmids pCMVΔR8.91 (expressing 
gag-pol) and pMD.G (expressing VSV-G) (kindly provided by Dr Ariberto 
Fassati, University College London, UK). Lentiviral stocks were concentrated 
using Lenti-XTM Concentrator (Clontech, St-Germain-en-Laye, France) and 
titers were obtained with Lenti-XTM qRT-PCR Titration kit (Clontech). For 
transduction, AML and control cells were plated onto 12 well plates at 5 x 104 
cells/well/0.5ml. Cells were infected with lentiviral stocks at an MOI of 15 in 
presence of 8 μg/ml Polybrene®. Transduced cells were analysed by flow 
cytometry (Accuri, BD biosciences), real-time-PCR (Roche) and Western 
blotting.  
 
Clonogenic methylcellulose assays 
Control CD34+ HSC, AML cell lines and primary AML cells (1×103 to 5×104 
cells) were plated in methylcellulose medium (R&D systems, Abingdon, UK) 
and colonies were visualised, measured and counted after 10-15 days. 
 
 9 
BMSC-AML cell adhesion assay 
BMSCs were grown in 96-well plates. AML cell lines and primary AML cells 
were incubated with 2.5 µM calcein-AM for 1 h at 37°C and 5% CO2. The 
fluorescence-labeled AML cells were added into stromal cell coated 96-well 
plates and incubated for the indicated time points. Nonadherent calcein-
labeled cells were removed by gently washing and adherent cells were 
quantitated in a fluorescence multiwell plate reader. 
 
PCR gene array expression analysis 
CD34+ control cells, AML cell lines and primary AML cells were left untreated 
or pretreated with 5 µM ibrutinib for 16 h. mRNA was isolated and reverse-
transcribed to obtain cDNA.  cDNA was incubated on an NF-B Signaling 
Pathway RT2 qPCR array (SABiosciences, Crawley, UK) according to the 
manufacturer’s instructions. This array contains 84 key genes involved in the 
NF-B signal transduction pathway and several controls. Target genes were 
normalized to control GAPDH expression and expressed as fold change 
relative to unstimulated control. 
 
BTK occupancy 
Primary AML cells and U937 were treated with increasing doses of ibrutinib 
(1nM-1000nM) for 1 hour. Cells were then washed in PBS and frozen at -80C. 
BTK occupancy was performed as described previously {Honigberg, 2010 
#8165}. 
 
Statistical analyses 
Student’s T test was performed to assess statistical significance from controls. 
Results with P < 0.05 were considered statistically significant (*). Results 
represent the mean ± SD of 3 independent experiments. For Western blotting, 
data are representative images of 3 independent experiments. 
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Results 
BTK is expressed and constitutively phosphorylated in AML. 
It has been recently reported that the non-receptor tyrosine kinases LYN and 
SYK, which have been shown to play an important role in normal B cell 
differentiation and hematopoietic signalling, are potential targets for AML 
therapy 31,32. As both LYN and SYK are known to activate BTK in 
haematologic cells 33,34 and BTK mRNA had previously been reported to be 
expressed in AML 24 we examined the basal activity levels of BTK in human 
AML. Initially we determined the frequency of BTK expression in human 
primary AML blasts and how its level of expression compares to normal 
CD34+ HSC. Real-time assessment of BTK mRNA in 25 primary human AML 
patients and 3 AML cell lines, showed it to expressed at comparable levels to 
control CD34+ HSC (not shown). Indeed, total BTK protein expression in AML 
samples (Figure 1A) shows its expression in these cells.  However, using 
phosphorylation at Y223 as a marker of BTK activation (Figure 1A), we 
identified a significant correlation between phospho BTK and total BTK 
expression in the AML samples.  Immunocytochemical analysis showed (in all 
but one case) there was an average 3 times greater BTK activity in AML cells 
than was present in comparator non-malignant CD34+ cells (Figure 1B and 
1C). We also tested phosphorylation at Y551. Although we could not detect a 
signal by Western blotting, immunocytochemical analysis of AML cell lines 
showed similar results to that observed with Y223 (data not shown). These 
observations showed that BTK was not only ubiquitously expressed in our 
patients AML but had increased activity (as measured by phosphorylation 
relative to non-malignant CD34+ cells) in over 90% of the primary AML patient 
samples tested, Taken together this implies that BTK may be functionally 
significant in human AML  
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Pharmacological inhibition of BTK induces cell death in primary AML 
blasts. 
Since the irreversible BTK inhibitor, ibrutinib has been shown to be cytotoxic 
in-vitro in CLL, MCL and MM 18,35,36, we next asked whether BTK inhibition 
would reduce cell viability in primary AML blasts. However, we first wanted to 
determine the level of occupancy of BTK by ibrutinib in AML cells. To do this 
we treated AML#22 and U937 with increasing doses of ibrutinib (3-1000nM) 
for 1 hour, cells were washed in PBS and frozen at 80C. By using the 
fluorescently tagged ibrutinib derivative PCI-33380 {Honigberg, 2010 #8165}, 
we found that 10 nM of ibrutinib was sufficient to fully occupy the active site of 
Btk in AML#22 and U937. These results mimic the results observed in CLL.  
Next, we tested the in-vitro activity of ibrutinib in a spectrum of primary AML 
cells from a wide age spectrum of adult patients and across a range of WHO 
AML subclasses (Supplementary Table 1). AML cells from 25 patients were 
treated with increasing concentrations of ibrutinib for 72 h. We found that 
ibrutinib exhibited a significant induction of cytotoxicity in AML patient cells 
(Figure 2A). IC50s were calculated for all AML patient samples 
(Supplementary Table 2). Cell death was examined separately by annexin-V 
and propidium iodide staining. We found that ibrutinib as a single agent at 
concentrations of 1 µM and 5 µM induced early apoptosis (annexin-V positive 
only) in AML (Supplementary Figure 1). We also examined the viability of 4 
AML cell lines in response to ibrutinib. The results showed that only U937 had 
significant induction of cytotoxicity in response to ibrutinib (IC50 ~ 2.6 µM) 
(Supplementary Table 2). Primary AML blasts were significantly more 
sensitive to ibrutinib than comparator CD34+ HSC (IC50s > 20 µM) for the 
control CD34+ HSC shown in Supplementary Table 2).  Correlation analysis 
of the data from BTK phosphorylation (Figure 1C) and ibrutinib IC50 levels 
(Supplementary Table 2) showed that there was a high correlation between 
high BTK phosphorylation and cytotoxicity to ibrutinib (Figure 2B). Figure 2C 
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shows the effect of ibrutinib on AML cell lines. As a control/comparator we 
tested the cytotoxic effects of ibrutinib in primary human CLL cells and 
showed levels of cytotoxicity (IC50s ~ 5 µM) in primary CLL cells similar to 
that achieved in AML at equivalent concentrations of the drug (Supplementary 
Figure 2) and compatible with in-vitro CLL data previously published (cytotoxic 
IC50s 5 – 50 µM)37. 
 
Ibrutinib inhibits AML proliferation 
We next explored the effect of ibrutinib on AML blast colony formation in 
methylcellulose compared to normal CD34+ myeloid progenitor cells. AML 
samples were more sensitive to the effects of ibrutinib at concentrations of 1 
µM, 5 µM and 10 µM than normal CD34 myeloid progenitor cells (Figure 3A).  
These observations show that in AML cytotoxicity can be achieved at ibrutinib 
concentrations not toxic to non-malignant normal residual CD34 positive cells.  
 
Next we examined the effects of ibrutinib on AML proliferation in response to 
cytokines known to induce proliferation in AML blasts {Vellenga, 1987 
#8501}{Westermann, 1996 #8502}. We used IL-3, GM-CSF, SCF and TNF to 
induce proliferation of AML blast. Pre-treatment of these AML blasts with 
ibrutinib (10-1000 nM) inhibited proliferation in IL-3, GM-CSF, SCF but not 
TNF treated cells (figure 3B).  
 
Genetic inhibition of BTK reduces colony formation from AML cells 
We next evaluated the genetic inhibition of BTK in AML cell lines and AML 
blasts. To do this we generated lentivirus-mediated long-term BTK knockdown 
using targeted artificial microRNA (BTK-targeted miRNA) and visualisation of 
infected cells by a concurrently expressed GFP signal tag.  These constructs 
induced GFP expression and BTK knockdown confirmed for up to 16 days by 
real-time PCR and protein expression (Figure 4A and B) and the role of BTK 
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in cell viability and long-term clonogenic assays was assessed. The 
introduction of BTK-specific miRNA dramatically inhibited the proliferation of 
U937 but had no effect on TF-1 cells (Figure 4C) which show control levels of 
pBTK activity.  With BTK-miRNA targeted knockdown we saw a reduction in 
methylcellulose colony formation in high pBTK expressing primary AML blasts 
and U937 [3/3 samples tested] but not in low pBTK expressing AML blasts 
and TF-1 [3/3 samples tested] or non-malignant CD34+HSC, compared to 
control-miRNA targeted cells (Figure 4D) suggesting when present pBTK 
appears to play a central role in AML proliferation and maintenance in these 
cells.  
 
Ibrutinib inhibits NF-κB survival genes in AML. 
We and others have previously reported that BTK is involved in p65-mediated 
transactivation during NF-κB activation in macrophages and malignant plasma 
cells 12,38.  As p65 phosphorylation is therefore necessary for induction of NF-
κB /p65-dependent gene expression in other haematologic cells 9,  we sought 
to determine if a similar role for BTK exists in AML.  To do this we employed a 
PCR-based NF-κB gene expression array by examining the RNA expression 
of 84 NF-κB.genes from control CD34+ HSC, primary AML cells and AML cell 
lines treated with ibrutinib 5 µM for 16 h. Results showed that ibrutinib 
dramatically reduced the expression of NF-κB target genes from AML patient 
cells with high BTK phosphorylation but not CD34+ HSC and AML cells with 
low BTK phosphorylation levels (Supplementary Figure 3A). A similar pattern 
of genes regulation was observed in U937 and TF-1 in which BTK was 
knocked-down by BTK-targeted miRNA (Supplementary Figure 4).  
 
To validate the results obtained with the PCR NF-κB arrays, we examined the 
expression of the genes highlighted above with quantitative RT-PCR. The 
quantitative RT-PCR analysis confirmed our initial observation that decreases 
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in the expression of NF-κB survival genes and NF-κB transcription factors was 
seen in response to the BTK inhibitor (Supplementary Figure 3B). Thus, 
modulation of BTK activity or expression results in selective effects on known 
NF-κB target survival genes. 
 
To further verify the involvement of NF-κB, and specifically p65 we treated 
AML cells with ibrutinib and by Western blotting examined p65 
phosphorylation. In primary AML blasts and AML cell lines we found that 
ibrutinib can inhibit p-p65 expression in high pBTK cells (2/2 samples tested) 
but not in low pBTK expression AML cells (2/2 samples tested) (Figure 5A).  
This observation was confirmed on AML cell lines U937 and TF-1 with BTK 
knockdown (Figure 5B). To determine if BTK inhibition had an effect on NF-κB 
nuclear activity we examined p50, p65 and c-Rel binding activity in AML blasts 
and AML cell lines. We found that ibrutinib significantly effected p50 and p65 
binding activity but not c-Rel (Figure 5C). 
 
Silencing BTK inhibits the AKT pathway in AML cells 
The PI3K/AKT pathway is frequently found to be activated in AML 39,40.  AKT 
phosphorylation on Ser473, assayed by Western blotting analysis of purified 
blast cells, can be detected in 50-80% of AML patients 41,42 . The mechanisms 
leading to PI3K/AKT activation in AML are not completely clear. The p110 
isoform of class IA PI3K, is always expressed in AML cells, whereas the 
p110 and p110β isoforms are heterogeneously expressed and the frequency 
of p110γ isoforms is unknown 43,44. Moreover, inhibition of BTK by ibrutinib 
has been shown to inhibit AKT phosphorylation in CLL and MCL {Herman, 
2011 #5689}{Chang, 2013 #8503}. 
 
Here we hypothesised that BTK was upstream of PI3K/AKT. To verify the role 
of BTK in constitutively active PI3K/AKT we treated U937 and TF-1 cell lines 
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with 1 µM ibrutinib for various times and extracted protein lysates. We then 
analysed these extracts for phosphorylated AKT at ser473 by Western 
blotting. Since ERK has also been shown to be inhibited by ibrutinib we also 
examined pERK levels in the same samples. Figure 5D shows that expression 
of phospho AKT and phospho ERK in U937, but not TF-1, is reduced in 
response to ibrutinib when compared to total AKT and ERK and β-actin. To 
validate the results obtained with ibrutinib we also analysed pAKT in U937 
with BTK437 KD. This showed that U937 treated with BTK437 KD had 
significantly reduced pAKT (Figure 5E). To further validate these observations 
we examined pAKT and pERK levels in primary AML in response to various 
concentrations of ibrutinib (3-1000nM). Figure 5F demonstrates that even at 
low levels of ibrutinib pAKT and pERK are inhibited in primary AML.  These 
results confirm that BTK is upstream of constitutively active PI3K/AKT and 
pERK signalling in human AML.  
 
Pharmacological inhibition of BTK enhances the effect of conventional 
chemotherapy in reducing cell viability and colony formation of AML 
blasts 
Chemotherapeutics frequently act synergistically and are often used clinically 
in combination. Here we looked to determine if ibrutinib could act 
synergistically with either cytarabine or daunorubicin, two widely used drugs in 
the treatment of AML.  In 48 h cultures of AML patients cells and cell lines, 
ibrutinib significantly increased cytotoxicity, when in combination with either 
cytarabine (0.1 and 0.5 μM) or daunorubicin (0.1 and 0.05 μM) (Figure 6A). 
Furthermore, in assays of primary human AML blasts ibrutinib when added to 
cytarabine reduced its IC50 by a median of 1.5 fold (range 0.18 – 3.55, n = 5) 
and when added to daunorubicin reduced the IC50 by a median of 3.1 fold 
(range 0.72 – 15.14, n = 5). Ibrutinib had no effect on the cytarabine and 
daunorubicin IC50s of non-malignant CD34+ cells (Supplementary Table 2). 
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Similarly ibrutinib augmented the cytotoxic effect of both cytarabine and 
daunorubicin to AML in colony forming cell assays (Figure 6B)  
 
Ibrutinib inhibits AML cell adhesion to BMSCs 
The interaction between AML blasts and the BM micro-environment is critical 
in regulating tumor survival and chemotherapy resistance. Inhibiting AML blast 
adhesion to BMSCs via the CXCR4-SDF-1 axis or by VLA4-VCAM/fibronectin 
interactions via the PI-3K/AKT/Bcl-2 signalling pathway is associated with 
improvements in tumor cytotoxicity 45,46. Because we found BTK functions 
directly upstream of AKT in AML blasts and as BTK inhibition with ibrutinib is 
known to perturb the interaction between the tumor cell and micro-
environment in CLL and myeloma 15,37, we sought to establish whether BTK 
functions in the important relationship between the AML tumor cells and the 
BM stromal niche that protect them.  To this end we used a calcein-AM 
fluorescence-based adhesion assay to determine if BTK inhibition by ibrutinib 
affects binding of AML cell lines and AML blasts to BMSCs. Figure 7A shows 
a representative example of the calcein-AM treated THP-1 cells on BMSCs 
after an 8 h co-culture with and without ibrutinib treatment. Overall treatment 
with various ibrutinib concentrations ≥ 0.1 µM significantly reduced the 
adhesion of AML cell lines and primary AML blasts to BMSCs (Figure 7B and 
7C) regardless of the BTK phosphorylation status of the AML cells. Moreover, 
the concentration needed to significantly inhibit AML-BMSC adhesion of 0.1 
µM has little or no effect on cytotoxicity of primary AML cell and AML cell lines 
(Figure 2A and C). These results demonstrated that ibrutinib effectively 
disrupts the interactions between AML cells and BMSC.  
 
BMSCs provide no protection for AML blasts from ibrutinib induced 
apoptosis 
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Because others have shown that BMSC can protect AML cells from 
chemotherapy-induced apoptosis 45-47, we wanted to assess the anti-leukemic 
efficacy of ibrutinib in AML blasts under BMSC co-culture conditions. To do 
this we cultured AML blasts from AML#17 (low pBTK) and AML#19 (high 
pBTK) alone or co-cultured with BMSCs, in the presence or absence of 
ibrutinib. Ibrutinib induced apoptosis in a concentration-dependent manner in 
AML#19 cells cultured alone or co-cultured with BMSCs, as determined by 
annexin-V staining (Figure 7D). No apoptosis was observed in AML#17 cells 
treated with ibrutinib either cultured alone or co-cultured with BMSCs. The 
effect of ibrutinib on AML#17 was anticipated as ibrutinib had not previously 
been shown to be cytotoxic to this sample. These findings show that inhibition 
of BTK activity with ibrutinib induces apoptosis in AML cells in response to 
ibrutinib alone even when co-cultured with BMSCs. However, as the stromal 
cells are known to protect AML from conventional cytotoxic drugs such as 
cytarabine, ibrutinib delivers a dual anti-leukemic effect by (i) releasing 
leukemic cells from the cytotoxic protecting microenvironment and (ii) direct 
cytotoxicity independent of stromal detachment. 
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Discussion 
Outcomes for the 75% of patients who get AML over the age of 60 remain 
generally poor, largely because the intensity and side effects of existing 
curative therapeutic strategies (which are commonly used to treat younger 
fitter patients) coupled to patient co-morbidities, frequently limit their use in 
this older less fit population. Consequently, there is an urgent need to identify 
pharmacological strategies in AML, which are not only effective but can be 
tolerated by the older less well patient. It is envisaged that treatments which 
target tumor-specific biology will help realise this goal. 
 
In this work, we build upon the observations that SYK and LYN, two non-
receptor tyrosine kinases, have been identified as possible AML targets 31,32. 
Downstream of SYK and LYN is BTK, a cytoplasmic tyrosine kinase widely 
expressed in hematopoietic cells and long known to be critical in B cell 
differentiation and survival pathways. BTK is a member of the Btk/Tec family 
of tyrosine kinases 48. Like other Btk family members, it contains a pleckstrin 
homology (PH) domain and Src homology SH3 and SH2 domains 19. Btk 
activation has been implicated in a variety of hematopoietic cellular responses 
and there is a growing literature supporting the role of BTK in a spectrum of B 
cell-derived hematological malignancies 18. In our studies we demonstrate that 
BTK is expressed and constitutively active in circa 90% of AML samples 
tested (relative to normal CD34+ cells) and furthermore AML growth and 
survival appears to be dependent on the presence of BTK. 
 
Ibrutinib (formally PCI-32765) is a selective covalent inhibitor of BTK. It is 
rapidly absorbed, potently irreversibly binds to BTK then is rapidly renally 
excreted 49, and it shows selectivity for BTK against a panel of kinase 
enzymes. To recapitulate this on/off phenomena in vitro, a 1 h pulse exposure 
of cells to 5 µM ibrutinib followed by washout has been shown to fully inhibit 
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BTK gene expression and furthermore minimises in vitro non-specific toxic 
effects in these experiments.  Early phase studies in CLL and lymphoma have 
produced not only particularly encouraging results but have also shown the 
drug to be generally well tolerated with limited toxicity 14,50. In our studies, the 
majority (12/21) of primary patient AML samples responded in a 
concentration-dependent manner, with an IC50 on or below the 
concentrations used in similar CLL studies 36,50. Thus, these observations 
suggest that inhibition of BTK in AML could be achieved with the doses 
currently used in clinical trials for CLL and lymphoma. 
 
Ibrutinib enabled us to reduce the IC50 of daunorubicin and cytarabine by 
approximately 3.5 and 1.5 fold respectively in primary AML samples but did 
not change the sensitivity of control non-malignant CD34+ cells to these 
cytotoxic drugs. This leads us to hypothesise whether in the future regimens 
including BTK inhibition may permit dose reductions of the cytotoxic drugs but 
maintain cytotoxic efficacy. If such approaches were associated with a more 
favourable side effect profile, there would be scope for their use across a 
greater spectrum (including age and co-morbidities) of AML patients than 
standard dose cytotoxics alone.  
 
In this study we describe a significant correlation between BTK Y223 
phosphorylation and the cytotoxicity of ibrutinib as measured by viability, 
apoptosis, and colony formation in methylcellulose (Figures 2A-D). In contrast, 
ibrutinib had minimal effects on apoptosis in control CD34+ HSC, AML 
samples and cell lines with low BTK Y223 phosphorylation. However, some 
AML samples that exhibited Y223 phosphorylation, such as AML#17 were 
relatively insensitive to ibrutinib whereas AML#7 with lower levels of Y223 
phosphorylation were very sensitive, suggesting that at least in vitro there are 
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factors other than the degree of BTK phosphorylation that may modify 
responsiveness to ibrutinib. 
 
Interestingly, we showed that AML blasts express BTK mRNA or protein at 
levels comparable to that observed in human CD34+ HSC. This demonstrates 
that the high BTK activity seen in this study is not primarily due to differential 
BTK expression, but probably more the result of upstream BTK regulators. 
Likely candidates include SYK and LYN, both of which have been shown to 
have constitutive activity in AML.  Determining the mechanism of activation of 
BTK in AML is under investigation, however, we have demonstrated evidence 
of both AKT signalling alteration and NF-κB gene expression and activity after 
ibrutinib treatment or BTK knockdown. This suggests that BTK is involved in 
pro-survival signals within AML. 
 
Leukaemia stem cells can infiltrate the bone marrow niche and may hijack the 
normal homeostatic processes, leading to enhanced self-renewal, proliferation 
and resistance to chemotherapeutic agents 47. Moreover drug strategies that 
disrupt the interaction between the AML tumor cell and its microenvironment 
appear to increase the cytotoxicity of conventional chemotherapies 45,46. 
Ibrutinib in the lymphoid malignancies appears to function in-part by disrupting 
the interaction between the tumor cell and the bone marrow/lymph node 
niche. In AML we report that ibrutinib as well as being directly cytotoxic to 
AML in vitro also inhibits cell adhesion to bone marrow stromal cells and that 
the same BMSC do not confer any protection from ibrutinib-induced 
apoptosis.  This data leads us to hypothesize that ibrutinib will improve the 
efficacy of standard chemotherapeutic drugs in patients with AML, not only by 
directly potentiating cytotoxicity of the cells, but additionally by perturbation of 
tumor cell adhesion to the microenvironment stromal cells that protect and 
maintain them. 
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In conclusion, we show that BTK is activated and functional in primary AML 
blasts. We demonstrate that the majority of primary AML blasts display a 
therapeutic response to BTK inhibition, with efficacy on cell growth, adhesion 
and colony formation capacity. With an orally available, well-tolerated BTK 
inhibitor currently in clinical trials in other haematological malignancies, the 
results reported here should have immediate relevance for clinical testing of 
ibrutinib in patients with AML. Furthermore, these results provide a rationale 
for combining ibrutinib with conventional AML therapies and exploring the 
opportunities for lowering the doses of daunorubicin and cytarabine in 
combination with BTK inhibition. 
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Figure Legends 
Figure 1. BTK is highly expressed and constitutively phosphorylated in 
AML. (A) Control CD34+ cells, AML patient cells and AML cell lines measured 
for constitutive levels of BTK phosphorylation by Western blotting, blots re-
probed for wild type BTK and β-actin to show BTK expression and sample 
loading respectively. (B) Primary CD34+ cells, AML cells and AML cell lines 
were analysed for phosphorylated BTK (Y223) (green) and total BTK (red) by 
immunocytochemistry. DAPI nuclear stain is shown in blue. (C) Using the 
immunocytochemical images captured, phospho-BTK was calculated as a 
percentage of total BTK. Values indicate the mean ± SEM from at least 5 
individual experiments, sampling at least 10 representative cells from each 
view.  * indicates statistical significance of P < 0.05 between the different 
treatment groups using Student’s T test. 
 
 
Figure 2. BTK occupancy by the BTK inhibitor ibrutinib and 
pharmacological inhibition of primary AML blasts. (A) AML blasts and the 
AML cell line U937 were treated with increasing doses of ibrutinib for 1 h and 
then assayed for BTK occupancy using ........ (B) AML blasts and CD34+ 
control cells were treated with increasing doses of ibrutinib (0.1 – 10 µM) for 
72 h and then assessed by Cell TitreGlo. Data were normalised to DMSO 
treated cells and represents the means ± SD, n = 3. (C) Correlation analysis 
of IC50 values of AML blasts treated with ibrutinib and % BTK 
phosphorylation. (D) AML cell lines were increasing doses of ibrutinib (0.1 – 
10 µM) for 72 h and then assessed by Cell TitreGlo. Data were normalised to 
DMSO treated cells and represents the means ± SD, n = 3. 
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Figure 3. Ibrutinib antagonises AML colony forming and cell 
proliferation. (A). AML blasts AML cell lines and CD34+ control cells were 
treated with 0.5, 1, 5 and 10 µM ibrutinib and colony forming assays were 
performed to show the number of colonies. Data were normalised to DMSO 
treated cells (B) Primary AML blasts (n=6) were pretreated with increasing 
doses of ibrutinib (0.01-1 µM) for 1 hour and then treated with either GM-CSF 
(ng/ml), SCF (10ng/ml) IL-3 (10ng/ml) and TNF (10ng/ml) for 72 hours. Data 
were normalised to DMSO treated cells.   
 
Figure 4. Genetic inhibition of BTK inhibits cell viability in AML cell lines. 
AML cell lines (TF-1 and U937) were transduced with BTK-targeted miRNA 
GFP-tagged lentiviral constructs. (A) Transfected cells were measured for 
GFP expression using flow cytometry for two BTK targeted miRNA (BTK437 
and BTK1092) in TF-1 cells. RNA was extracted from TF-1 and U937 cells 
transduced with BTK-targeted and non-silencing miRNA control constructs 
and examined for BTK expression by real-time PCR at the indicated times. 
mRNA expression was normalized to GAPDH mRNA levels. (B) Protein 
extracts were also obtained and Western blot analysis was conducted for 
pBTK and BTK protein levels. (C) TF-1 and U937 were transduced with either 
BTK-targeted miRNA or non-silencing control miRNA construct for 72 h, Cell 
number was assessed by Cell TitreGlo assay. (D)  AML blasts, AML cell lines 
and CD34+ HSC were transduced with BTK-targeted miRNA and control 
miRNA constructs and colony forming assays were performed to show the 
number of colonies detected. In all panels values indicate the mean ± SD from 
3 independent experiments. * indicates statistical significance of P < 0.05 
between the different treatment groups. 
 
Figure 5. AKT and NF-κB activity in AML cells is augmented by BTK 
inhibition. (A) AML cell lines and AML blasts were treated with 1 and 5 µM of 
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ibrutinib for 4 h and then whole cell extracts were prepared and Western blot 
analysis was conducted for p-p65 and β-actin protein levels. (B)  AML cell 
lines (TF-1 and U937) were transduced with BTK-targeted miRNA GFP-
tagged lentiviral constructs (BTK437 and BTK1092) as well as negative 
control. Protein extracts were also obtained and Western blot analysis was 
conducted for p-p65 and β-actin protein levels. (C) AML cell lines and AML 
blasts were treated with 1 and 5 µM of ibrutinib for 4 h and then nuclear 
extracts were prepared and Western blot analysis was conducted for nuclear 
p50 and TBP protein levels. (D)  AML cell lines (TF-1 and U937) were 
transduced with BTK-targeted miRNA GFP-tagged lentiviral constructs 
(BTK437 and BTK1092) as well as negative control. Nuclear extracts were 
prepared and Western blot analysis was conducted for nuclear p50 and TBP 
protein levels. (E) AML cell lines and were treated with 5 µM of ibrutinib for 
various times and then whole cell extracts were prepared and Western blot 
analysis was conducted for pAKT-S473, pAKT-T308, total AKT and β-actin 
protein levels. (F)  AML cell line (U937) were transduced with BTK-targeted 
miRNA GFP-tagged lentiviral constructs (BTK437) as well as negative control. 
Whole cell extracts were prepared and Western blot analysis was conducted 
for pAKT-S473, total AKT and β-actin protein levels. 
 
Figure 6. Reduced viability and colony formation of AML cells following 
inhibition of BTK in combination with conventional chemotherapy. (A) 
AML blasts and CD34+ control cells were either untreated or treated with 
ibrutinib (1 µM) for 8 h and then treated with either cytarabine (0.1 µM or 0.5 
µM) or daunorubicin  (0.05 µM or 0.1 µM) for 72 hours and then assessed by 
Cell TitreGlo. Values indicate means ± SD, n = 3. (B) AML cells and control 
cells were either untreated or treated with ibrutinib (1 µM) for 8 h and then 
treated with either cytarabine (0.1 µM) or daunorubicin (0.05 µM) and then 
colony forming assays were performed to show the number of colonies.  In all 
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panels values indicate the mean ± S.D. from 3 independent experiments.  * 
indicates statistical significance of P < 0.05 between the different treatment 
groups using Student’s T test.  
 
Figure 7. AML-BMSC adhesion and protection is disrupted by Ibrutinib. 
(A) Light and fluorescence microscopic images show co-cultured calcein-AM 
treated THP-1 cells and BMSC with and without 0.5 µM ibrutinib treatment for 
8 h. (B) Percentage of AML cell lines and (C) primary AML blasts attached to 
the primary AML BMSCs in the co-culture setting in the presence and 
absence of various concentrations of ibrutinib for 8 h. (D) AML blasts from 
AML#17 (low pBTK) and AML#19 (high pBTK) were left alone or co-cultured 
with BMSCs, in the presence or absence of various concentrations of ibrutinib 
for 48 h and then stained for annexin-V and analysed by flow cytometry. In all 
panels values indicate the mean ± SD from 3 independent experiments. * 
indicates statistical significance of P < 0.05 between the different treatment 
groups. 
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